0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Chronic Obstructive Pulmonary Disease (COPD) Market Insight, Epidemiology and Market Forecast 2028
Published Date: February 2019
|
Report Code: DELV-Mark-24
Home | Market Reports | Health | Health Conditions | Respiratory Conditions
Chronic Obstructive Pulmonary Disease Market Insight Epidemiology and Market Forecast 2028

Chronic Obstructive Pulmonary Disease (COPD) Market Insight, Epidemiology and Market Forecast 2028

Code: DELV-Mark-24
Report
February 2019
100 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Chronic Obstructive Pulmonary Disease (COPD) epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Chronic Obstructive Pulmonary Disease (COPD) Understanding and Treatment Algorithm
The market report provides the overview of the Chronic Obstructive Pulmonary Disease (COPD) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Chronic Obstructive Pulmonary Disease (COPD) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Chronic Obstructive Pulmonary Disease (COPD) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Chronic Obstructive Pulmonary Disease (COPD) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Chronic Obstructive Pulmonary Disease (COPD) market.

Chronic Obstructive Pulmonary Disease (COPD) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Chronic Obstructive Pulmonary Disease (COPD) Report Insights
• Patient Population in Chronic Obstructive Pulmonary Disease (COPD)
• Therapeutic Approaches in Chronic Obstructive Pulmonary Disease (COPD)
• Chronic Obstructive Pulmonary Disease (COPD) Pipeline Analysis
• Chronic Obstructive Pulmonary Disease (COPD) Market Size and Trends
• Chronic Obstructive Pulmonary Disease (COPD) Market Opportunities
• Impact of upcoming Therapies in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Chronic Obstructive Pulmonary Disease (COPD) Report Assessment
• Current Treatment Practices in Chronic Obstructive Pulmonary Disease (COPD)
• Unmet Needs in Chronic Obstructive Pulmonary Disease (COPD)
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Chronic Obstructive Pulmonary Disease (COPD) market
• Organize sales and marketing efforts by identifying the best opportunities for Chronic Obstructive Pulmonary Disease (COPD) market
• To understand the future market competition in the Chronic Obstructive Pulmonary Disease (COPD) market.

1. Report Introduction
2. Chronic Obstructive Pulmonary Disease (COPD) Market Overview at a Glance
2.1. Market Share Distribution of Chronic Obstructive Pulmonary Disease (COPD) in 2016
2.2. Market Share Distribution of Chronic Obstructive Pulmonary Disease (COPD) in 2028
3. Disease Background and Overview: Chronic Obstructive Pulmonary Disease (COPD)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chronic Obstructive Pulmonary Disease (COPD) in 7MM
4.3. Total Prevalent Patient Population of Chronic Obstructive Pulmonary Disease (COPD) in 7MM – By Countries
5. Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.1.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.1.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.1.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.1.6. Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.4.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.4.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.4.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.4.6. Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.5.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.5.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.5.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.5.6. Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.6.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.6.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.6.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.6.6. Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.7.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.7.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.7.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.7.6. Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.8.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.8.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.8.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.8.6. Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.9.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.9.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.9.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.9.6. Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Chronic Obstructive Pulmonary Disease (COPD)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Chronic Obstructive Pulmonary Disease (COPD)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Chronic Obstructive Pulmonary Disease (COPD) : 7MM Market Analysis
12.1. 7MM Market Size of Chronic Obstructive Pulmonary Disease (COPD)
12.2. 7MM Percentage Share of drugs marketed for Chronic Obstructive Pulmonary Disease (COPD)
12.3. 7MM Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Products
13. Chronic Obstructive Pulmonary Disease (COPD) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Chronic Obstructive Pulmonary Disease (COPD) in United States
13.1.2. Percentage Share of drugs marketed for Chronic Obstructive Pulmonary Disease (COPD) in United States
13.1.3. Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Chronic Obstructive Pulmonary Disease (COPD) in Germany
13.2.1.2. Percentage Share of drugs marketed for Chronic Obstructive Pulmonary Disease (COPD) in Germany
13.2.1.3. Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Chronic Obstructive Pulmonary Disease (COPD) in France
13.2.2.2. Percentage Share of drugs marketed for Chronic Obstructive Pulmonary Disease (COPD) in France
13.2.2.3. Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Chronic Obstructive Pulmonary Disease (COPD) in Italy
13.2.3.2. Percentage Share of drugs marketed for Chronic Obstructive Pulmonary Disease (COPD) in Italy
13.2.3.3. Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Chronic Obstructive Pulmonary Disease (COPD) in Spain
13.2.4.2. Percentage Share of drugs marketed for Chronic Obstructive Pulmonary Disease (COPD) in Spain
13.2.4.3. Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Chronic Obstructive Pulmonary Disease (COPD) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Chronic Obstructive Pulmonary Disease (COPD) in United Kingdom
13.2.5.3. Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Chronic Obstructive Pulmonary Disease (COPD) in Japan
13.3.2. Percentage Share of drugs marketed for Chronic Obstructive Pulmonary Disease (COPD) in Japan
13.3.3. Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Table 6: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Table 7: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Table 12: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Table 15: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Table 16: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Table 17: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Table 22: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Table 27: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Table 31: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Table 32: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Table 37: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Table 42:7MM- Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Table 45: United States-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Table 48: Germany-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Table 51: France-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Table 54: Italy-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Table 57: Spain-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Table 60:UK-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Table 63: Japan-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Figure 7: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Figure 12: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Figure 16: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Figure 17: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Figure 22: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Figure 27: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Figure 32: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Figure 37: Treatable Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Figure 42:7MM- Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Figure 45: United States-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Figure 48: Germany-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Figure 51: France-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Figure 54: Italy-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Figure 57: Spain-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Figure 60:UK-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM (2016-2028)
Figure 63: Japan-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$6250
This license allows only one user to access the PDF.

Electronic (PDF)
$12500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$18750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

Global and United States Silicone Airway Stent Market Insights Forecast to 2027
Global and United States Silicone Airway Stent Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-9Y6703
Tue Aug 31 00:00:00 UTC 2021

Add to Cart

Global and Japan Asthma Inhaler Device Market Insights Forecast to 2027
Global and Japan Asthma Inhaler Device Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-12Y7065
Tue Aug 24 00:00:00 UTC 2021

Add to Cart

Global and United States Chronic Lung Diseases Treatment Market Size Status and Forecast 2021 2027
Global and United States Chronic Lung Diseases Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-13C7110
Tue Aug 24 00:00:00 UTC 2021

Add to Cart

Global and China Asthma Devices Market Insights Forecast to 2027
Global and China Asthma Devices Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-21J7057
Tue Aug 24 00:00:00 UTC 2021

Add to Cart